Lung Cancer (Diagnosis)NCT07439991
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
An observational study of Lung Cancer (Diagnosis) and Deep Vein Thrombosis (DVT), run by The First Hospital of Jilin University at 1 site in China.
Trial summary
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is: Which clinical, surgical, and laboratory factors are associated with the development of postoperative… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer (Diagnosis), Deep Vein Thrombosis (DVT), Venous Thromboembolism (VTE)
- What is being tested?
- Prospective Perioperative Data Collection
- How many people
- 900 participants
- Where
- 1 siteChina
- Study dates
- 1 Nov 2024to 30 Nov 2029
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adult patients undergoing surgical resection for lung cancer at the Department of Thoracic Surgery, First Hospital of Jilin University. Participants will be prospectively followed for 30 days postoperatively to assess the occurrence of deep vein thrombosis (DVT) and to identify perioperative risk factors. All patients meeting inclusion criteria and without exclusion criteria will be eligible.
Who may be able to join
- Age ≥ 18 years
- Patients undergoing surgical resection for lung cancer
- Postoperative hospital stay ≥ 48 hours
- Availability of perioperative clinical, laboratory, and imaging data
- Willingness to provide informed consent and participate in 30-day follow-up
Who cannot join
- Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery
- Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks
- Severe coagulation disorders or bleeding diseases
- Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection
- Concurrent major organ surgery (e.g., cardiac, liver surgery)
- Pregnancy or lactation
- Incomplete postoperative follow-up data
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Hospital of Jilin University, Department of Thoracic Surgery
Changchun, Jilin, 130021
Wei Liu, 86-13596083366, l_w01@jlu.edu.cn
About this study
Official title: Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:
Which clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?
Participants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.
- Being tested
- Prospective Perioperative Data Collection
- Medical subject headings
- Lung Neoplasms, Disease, Venous Thrombosis, Venous Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prospective Perioperative Data CollectionOther
The intervention involves the prospective collection of perioperative clinical, laboratory, and imaging data from adult patients undergoing lung cancer surgery. No therapeutic or diagnostic procedures beyond standard care are applied. Collected data will be used to identify risk factors for postoperative deep vein thrombosis (DVT) and to develop machine learning-based predictive models.
| Study group | Role | What they receive |
|---|---|---|
| VTE Group | Adult patients undergoing lung cancer surgery who develop postoperative deep vein thrombosis (DVT) within 30 days. Perioperative clinical, laboratory, and imaging data will be collected to identify risk factors and build predictive models. Receives: Other: Prospective Perioperative Data Collection | |
| Non-VTE Group | Adult patients undergoing lung cancer surgery who do not develop postoperative DVT within 30 days. Perioperative clinical, laboratory, and imaging data will be collected for comparison with the VTE group. Receives: Other: Prospective Perioperative Data Collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients
The primary outcome is the occurrence of postoperative deep vein thrombosis (DVT) within 30 days after lung cancer surgery, confirmed by Doppler ultrasound of the lower extremities. Perioperative clinical, laboratory, and imaging variables will be collected prospectively and analyzed to identify risk factors and develop machine learning-based predictive models for individual DVT risk.
Measured: From the day of lung cancer surgery to 30 days postoperatively
Secondary outcomes (1)
Identification of perioperative risk factors for postoperative deep vein thrombosis (DVT) in lung cancer surgery patients
Secondary outcomes include the evaluation of clinical, surgical, and laboratory variables associated with postoperative DVT within 30 days. Variables such as age, sex, BMI, comorbidities, tumor characteristics, operative details, and perioperative laboratory results will be analyzed using multivariate logistic regression and machine learning models to identify independent predictors of DVT.
Measured: From the day of surgery to 30 days postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start1 Nov 2024
- Primary completion1 Nov 2029 (estimated)
- Study completion30 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 900 participants (estimated)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- The First Hospital of Jilin University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07439991
- Sponsor's protocol ID
- JLUThorSurg-VTE02
- Status last verified
- Nov 2025
- First submitted
- 23 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery
- ClinicalTrials.gov ID
- NCT07439991
- Acronym / sponsor ID
- JLUThorSurg-VTE02
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- The First Hospital of Jilin UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Nov 2029 (estimated)
- Study completion
- 30 Nov 2029 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:
Which clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?
Participants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 30 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| VTE Group | – | Other: Prospective Perioperative Data CollectionAdult patients undergoing lung cancer surgery who develop postoperative deep vein thrombosis (DVT) within 30 days. Perioperative clinical, laboratory, and imaging data will be collected to identify risk factors and build predictive models. |
| Non-VTE Group | – | Other: Prospective Perioperative Data CollectionAdult patients undergoing lung cancer surgery who do not develop postoperative DVT within 30 days. Perioperative clinical, laboratory, and imaging data will be collected for comparison with the VTE group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult patients undergoing surgical resection for lung cancer at the Department of Thoracic Surgery, First Hospital of Jilin University. Participants will be prospectively followed for 30 days postoperatively to assess the occurrence of deep vein thrombosis (DVT) and to identify perioperative risk factors. All patients meeting inclusion criteria and without exclusion criteria will be eligible.
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Patients undergoing surgical resection for lung cancer
- Postoperative hospital stay ≥ 48 hours
- Availability of perioperative clinical, laboratory, and imaging data
- Willingness to provide informed consent and participate in 30-day follow-up
Key exclusion criteria (7 listed)
- Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery
- Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks
- Severe coagulation disorders or bleeding diseases
- Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection
- Concurrent major organ surgery (e.g., cardiac, liver surgery)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prospective Perioperative Data CollectionThe intervention involves the prospective collection of perioperative clinical, laboratory, and imaging data from adult patients undergoing lung cancer surgery. No therapeutic or diagnostic procedures beyond standard care are applied. Collected data will be used to identify risk factors for postoperative deep vein thrombosis (DVT) and to develop machine learning-based predictive models. | Other | Non-VTE Group, VTE Group |
Primary outcome
Incidence of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients
Time frame: From the day of lung cancer surgery to 30 days postoperatively
The primary outcome is the occurrence of postoperative deep vein thrombosis (DVT) within 30 days after lung cancer surgery, confirmed by Doppler ultrasound of the lower extremities. Perioperative clinical, laboratory, and imaging variables will be collected prospectively and analyzed to identify risk factors and develop machine learning-based predictive models for individual DVT risk.
1 secondary outcome
Identification of perioperative risk factors for postoperative deep vein thrombosis (DVT) in lung cancer surgery patients
Time frame: From the day of surgery to 30 days postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer (Diagnosis)
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
RecruitingPhase 1/2
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma, Advanced
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer (Diagnosis) and Deep Vein Thrombosis (DVT), run by The First Hospital of Jilin University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wei Liu (86-13596083366, l_w01@jlu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients (time frame: From the day of lung cancer surgery to 30 days postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.